Our study aims to examine the treatment outcomes of patients with non-neurogenic detrusorexternal sphincter dyssynergia (DESD) after the injection of botulinum toxin A (BTX-A, Botox®) to the external sphincter.
INTrODUcTION
Botulinum toxin A (BTX-A, Botox®) was first introduced in Urology by Dykstra 1 in 1988 for the treatment of detrusor sphincter dyssynergia in patients with spinal cord injury. Subsequent studies of sphincter spasticity in adult patients had significant positive results, especially decreased PVRU [2] [3] [4] [5] [6] [7] . The use of BTX-A in children has been further examined, including children with nonneurogenic neurogenic bladder dysfunction, with good outcomes [8] [9] .
Non-neurogenic functional bladder outlet obstruction (in the absence of anatomical abnormality) can arise from sphincter dyssynergia.
These may also be termed non-neurogenic neurogenic bladder, Hinman syndrome or external sphincter pseudodyssynergia. Essentially in DESD, there is urodynamic evidence of bladder outlet obstruction, secondary to a kinesiologic disassociation of the two groups of muscles that generally work in harmony (the detrusor and the external sphincter), in the absence of any neurological abnormalities.
High voiding pressures secondary to bladder outlet obstruction can lead to long-term renal damage. As such, traditional treatment modalities for DESD typically aim to reduce voiding pressures. These options include urethral stents, balloon dilatation Proceedings of Singapore Healthcare  Volume 22  Number 2  2013 and external sphincterotomy. Our study aims to show that adult patients with DESD can be treated successfully with the injection of BTX-A to the external sphincter, negating the need for drastic surgical measures.
METHODS
From December 2006 to March 2008, a total of nine patients were found to have DESD and treated. The treatment records of these patients were reviewed retrospectively. All patients were diagnosed with DESD with the aid of video urodynamic studies (UDS). DESD was recognised by the involuntary contractions of the external urethral sphincter during a detrusor contraction ( Fig. 1 ). The micturating cystogram showed ballooning of proximal urethra, associated with external sphincter 'pinching' (Fig. 2) . The dilatation of the proximal urethra in male patients confirmed that the level of obstruction was distal to the level of the prostatic urethra.
Pre-operative evaluation was similar in all patients and standardised. Patients kept a bladder diary, had a bedside ultrasound of the kidneys and bladder, and a renal function test. Urine microscopy and culture was done in all cases to exclude urinary tract infection.
Each patient received BTX-A (OnabotulinumtoxinA) injection of 50-100U, diluted with normal saline, to the external sphincter under local (LA) or general anaesthesia (GA). Male patients had the procedure conducted under GA, with the external sphincter identified under direct vision using a rigid cystoscope. Injections were done at four points, namely the 3, 6, 9 and 12 o'clock position, with 25U (diluted to 1ml) of BTX-A at each point. Female patients had the procedure under LA, with the injection done using an insulin syringe at the 3 and 9 o'clock position, with 25-50U (diluted to 1 ml). The procedure was done as a day surgery procedure. All patients recovered well and were discharged on the same day.
Post-operatively, these patients were assessed at the clinic four to six weeks later using uroflowmetry and bedside ultrasonography. The pre-operative and post-operative Qmax and PVRU were objectively compared using paired-samples t test (SPSS 16.0). A P <0.05 was considered to be statistically significant. Table 1 .
The mean pre-operative Qmax was 9.7±6.26 ml/s. This improved to 16.5±11.3 ml/s post-operatively. The mean difference in Qmax was 6.76±8.1 ml/s (P=0.037). There is a significant improvement in the pre-operative Qmax compared to the post-operative Qmax (Fig. 3 ). An uroflow trace demonstrates the dramatic improvement six weeks after treatment ( Fig. 4) .
Similarly, we compared the PVRU before and after treatment. The mean preoperative PVRU was 179.2±86.8 ml. This improved to 45.7±44.4 ml post-operatively. The mean difference in PVRU was 133.6±77.2 ml (P=0.001). The difference is also statistically significant (Fig. 5) . A summary all urodynamic findings is as shown in Table 2 . 
DIScUSSION
In today's urologic practice, BTX-A is widely established as part of the armamentarium for the treatment of refractory detrusor overactivity (DO). A multi-centre trial involving 10 European centres, showed an improvement in continence and quality of life after treatment 10 .
Local experience in managing neurogenic DO in patients with spinal cord injury with injection of BTX-A has also shown good results. There were improvements in continence, bladder capacity, decreased maximal detrusor pressures and better patient satisfaction 11 . At our institution, we previously evaluated the use of BTX-A as a treatment of idiopathic detrusor over-activity for 19 patients with symptoms of overactive bladder. Our prospective study showed improvement in both subjective and objective measurements posttreatment 12 .
The mechanism of action of BTX-A is through the inhibition of signal transmission at the neuromuscular junction. Botulinum toxin is 13, 14 .
Neurogenic DESD typically occur in patients with neurological pathology, for example, spinal cord lesions secondary to spinal cord injury, multiple sclerosis or transverse myelitis. Patients may have elevated intravesical pressures and PVRU.
Before Injection
After Injection Fig. 4 . Uroflow of a patient before and after treatment with BTX-A Treatment is needed to prevent recurrent urinary tract infections and upper tract complications, particularly if the patient has high detrusor leak point pressures (DLPP) 15 . However, the use of BTX-A for the treatment of non-neurogenic DESD in adult patients is not common.
Non-neurogenic DESD or Hinman syndrome was first described by Hinman in 1971. He described the non-neurogenic bladder in 14 boys aged eight years old, who had incontinence, infections and obstructive uropathy 16 . Current treatment consists of a combination of antibiotics, anticholinergics, alpha-blockers and bladder training. Clean intermittent self catherisation (CISC) may be required if patients have high PVRU.
Steinhardt et al were the first to describe the treatment of external sphincter dyssynergia using botulinum toxin for neurologically normal children 17 . This method of treatment was successfully repeated at several other centers in paediatric patients 18, 19 . Our study aims to study the efficacy of use of botulinum toxin in adult patients.
Video urodynamic studies are used to confirm the diagnosis of non-neurogenic DESD. We have elected to conduct this examination without the use of electromyography (EMG) unlike other centres. We have found that this approach is less invasive as it eliminates the need for needle electrodes. Surface EMG probes have the disadvantage of being inaccurate due to patient movement. In addition, the fluoroscopic method allows diagnosis of the level of obstruction, thereby allowing the exclusion of bladder outlet obstruction secondary to prostatic enlargement in our male patients.
Our results have shown a statistical difference in pre-treatment and post-treatment variables with increase in Qmax, and reduction in PVRU. This shows that BTX-A injection is a feasible form of treatment for non-neurogenic DESD.
However, treatment effect may be short-lived in some patients, with some requiring repeated injections (44.4%). This and the incurred cost seem to be the main disadvantage of repeated BTX-A injections. It is observed that in our series, that the time interval between the second and third injection (mean 11 months), is longer than the time interval for the first and second (mean 9.5 months). We also acknowledge the limitations of our study including the small sample size, and the retrospective nature of the study design. Ideally there should be a validated questionnaire evaluating the patient's symptoms pre-procedure and post-procedure.
Lately, there has been some concern with regards to the repeated, long-term use of BTX-A intradetrusor injections in patients with neurogenic bladder dysfunction. It is suggested that BTX-A may 
